In order to address the increasing complexity of the use of JAK inhibitors, an international working group led by Josef Smolen at MedUni Vienna has updated the 2019 guidelines in line with the latest scientific findings.
Rheumatoid arthritis is one of the most common inflammatory joint diseases. Thanks to modern medication, the disease can now be controlled much better, even if it cannot be cured.